Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

Journal of Clinical Oncology

Volumn 25, Issue 17, 2007, Pages 2434-2441

  Cavo, Michele ^a   Tosi, Patrizia ^a   Zamagni, Elena ^a   Cellini, Claudia ^a   Tacchetti, Paola ^a   Patriarca, Francesca ^a   Di Raimondo, Francesco ^a   Volpe, Ettore ^a   Ronconi, Sonia ^a   Cangini, Delia ^a   Narni, Franco ^a   Carubelli, Affra ^a   Masini, Luciano ^a   Catalano, Lucio ^a   Fiacchini, Mauro ^a   De Vivo, Antonio ^a   Gozzetti, Alessandro ^a   Lazzaro, Antonio ^a   Tura, Sante ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PROTEASOME INHIBITOR; RECOMBINANT ALPHA INTERFERON; THALIDOMIDE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 34347260711     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.2509     Document Type: Article

References (38)

1. Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832-3842, 1998
2. Cavo M, Benni M, Ronconi S, et al: Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: Final analysis of a randomized clinical study. Haematologica 87:934-942, 2002
3. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2:822-824, 1983
4. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
5. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875-1883, 2003
6. Barlogie B, Jagannath S, Desikan KR, et al: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999
7. Attal M, Harousseau JL, Facon T, et al: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003
8. Segeren CM, Sonneveld P, van der Holt B, et al: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study. Blood 101:2144-2151, 2003
9. Fermand JP: High dose therapy supported with autologous blood stem cell transplantation in multiple myeloma: Long term follow-up of the prospective studies of the MAG group. Haematologica 90:40, 2005 (suppl 1; abstr PL8.05)
10. Goldschmidt H: Single vs. double high-dose therapy in multiple myeloma: Second analysis of the GMMG-HD2 trial. Haematologica 90:38, 2005 (suppl 1; abstr PL8.02)
11. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 121:749-757, 2003
12. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
13. Soverini S, Cavo M, Cellini C, et al: Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double ASCT. Blood 102:1588-1594, 2003
14. Cavo M, Terragna C, Renzulli M, et al: Poor outcome with front-line ASCT in t(4;14) multiple myeloma: Low complete remission rate and short duration of remission. J Clin Oncol 24:e4-e5, 2006
15. Cavo M, Galieni P, Zuffa E, et al: Prognostic variables and clinical staging in multiple myeloma. Blood 74:1774-1780, 1989
16. Alvares CL, Davies FE, Horton C, et al: Long-term outcomes of previously untreated myeloma patients: Responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol 129:607-614, 2005
17. Nadal E, Giné E, Bladé J, et al: High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: Predictors of complete remission. Bone Marrow Transplant 33:61-64, 2004
18. Fermand JP, Katsahian S, Divine M, et al: High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23: 9227-9233, 2005
19. Barlogie B, Tricot G, Rasmussen E, et al: Total therapy 2 without thalidomide in comparison with total therapy 1: Role of intensified induction and posttransplantation consolidation therapies. Blood 107:2633-2638, 2006
20. Barlogie B, Tricot GJ, van Rhee F, et al: Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135:158-164, 2006
21. Barlogie B, Tricot G, Anaissie E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030, 2006
22. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
23. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
24. Dimopoulos MA, Spencer A, Attal M, et al: Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010). Blood 106:6a, 2005 (abstr 6)
25. Richardson PG, Blood E, Mitsiades CS, et al: A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458-3464, 2006
26. Fassas AB, Barlogie B, Ward S, et al: Survival after relapse following tandem autotransplants in multiple myeloma patients: The University of Arkansas total therapy I experience. Br J Haematol 123: 484489, 2003
27. Blade J, Rosinol L, Sureda A, et al: High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106:3755-3759, 2005
28. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
29. Barlogie B, Shaughnessy J, Tricot G, et al: Treatment of multiple myeloma. Blood 103:20-32, 2004
30. Durie BGM: New approaches to treatment for multiple myeloma: Durable remission and quality of life as primary goals. Clin Lymphoma Myeloma 6:181-190, 2005
31. Cavo M, Baccarani M: The changing landscape of myeloma therapy. N Engl J Med 354:1076-1078, 2006
32. Cavo M, Zamagni E, Tosi P, et al: Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for ASCT for multiple myeloma. Blood 106:35-39, 2005
33. Rajkumar VS, Hayman SR, Lacy MQ, et al: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:40504053, 2005
34. Oakervee HE, Popat R, Curry N, et al: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129:755-762, 2005
35. Harousseau JL, Marit G, Caillotd, et al: VELCADE/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): An interim analysis of the IFM 2005-01 randomized multicenter phase III trial. Blood 108:21a, 2006 (abstr 56)
36. Attal M, Harousseau JL, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 108: 3289-32294, 2006
37. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367:825-831, 2006
38. Mateos MV, Hernandez JM, Hernandez MT, et al: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase I/II study. Blood 108:2165-2172, 2006